BeOne Medicines (ONC) Brought Fresh ESMO 2026 Solid Tumor Data Into Focus

• BeOne Medicines (NasdaqGS:ONC) presented new first-in-human and dose-optimization data on several targeted oncology assets at ESMO 2026.
• The firm highlighted GPC3x4-1BB bispecific antibody data in hepatocellular carcinoma and early efficacy signals across multiple solid tumor types.
• BeOne reported results for a brain-penetrant PRMT5 inhibitor and CEA-targeting ADC in NSCLC, plus a Phase 3 CDK4 inhibitor trial in breast cancer.
• The fresh ESMO 2026 trial readouts for GPC3x4-1BB, PRMT5, CEA-ADC and CDK4 therapies sit within a wider pattern our research tracks. Check out 3 other big wins that BeOne Medicines investors should know about.

For readers interested in more ideas around oncology and data-driven drug development, the next stop is 34 healthcare AI stocks.

BeOne Medicines, a US based oncology specialist with a US$43.5b market cap, is building a pipeline aimed at solid tumors across the US, China, Europe, and other regions. The fresh early data set from ESMO 2026 feeds directly into that global treatment agenda.

How does the GPC3x4-1BB data reshape BeOne Medicines’ market opportunity in liver cancer?

The HCC study for BGB-B2033 reported a 36.0% confirmed ORR at the 450 mg three weekly dose in a heavily pretreated group where TKIs have shown about 5% ORR. Grade 3 or higher treatment related events appeared in 5.3% of patients and discontinuations in 2.1%. That mix of activity and tolerability positions BeOne to compete for later line liver cancer use where options are limited.

Does this ESMO package change the BeOne Medicines Narrative investors have been using?

The Narrative already leans on a broad late stage oncology pipeline and multiple proof of concept readouts through 2026, and this ESMO slate plugs neatly into that story. First in human and dose optimization data across HCC, NSCLC and HR+/HER2 negative breast cancer give concrete support to the idea that solid tumor assets can gradually complement BRUKINSA rather than leaving the story tied to one hematology pillar.

See how these catalysts shape BeOne Medicines' path to a $433 fair value.

What should investors watch next from these programs?

The clearest signpost is how BeOne converts these findings into registrational paths, starting with the planned Phase 3 program for BGB-B2033 at the 450 mg dose and progress in enrolling the global KANDELA-302 trial that opened in May 2026. Uptake of BGB-58067 and BG-C477 into later stage NSCLC studies, especially in MTAP deficient and CEAhigh segments, will also show whether the lung cancer franchise can move toward meaningful revenue contribution.

Add BeOne Medicines to your Watchlist and get alerts as these catalysts play out.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com